urothelial carcinoma

This page shows the latest urothelial carcinoma news and features for those working in and with pharma, biotech and healthcare.

Tecentriq approved in Europe for triple negative breast cancer

Other areas for planned expansion include previously untreated locally advanced or metastatic urothelial carcinoma (mUC), where Roche has just reported positive phase 3 results.

Latest news

Positive first-line phase 3 results for Tecentriq

advanced or metastatic urothelial carcinoma (mUC). Urothelial carcinoma is the most common type of bladder cancer, and accounts for around 90% of cases, with 30% of those considered to be advanced.
Lilly to withdraw Lartruvo, a first for accelerated approval failures

In recent times, several immunotherapy treatments have failed confirmatory studies. These include Roche’s Tecentriq and others in urothelial carcinoma, and Merck &Co’s Keytruda in gastric cancer, however the FDA
J&J’s targeted bladder cancer treatment gets US approval

We recognise the significant unmet need that persists in the treatment of men and women diagnosed with this form of urothelial carcinoma, and we have worked expeditiously to develop Balversa for ... We look forward to the continued development of
NICE green light for Imfinzi in groundbreaking early lung cancer treatment

Imfinzi is far behind that tally, with 2018 sales of $633m, based largely on its first indication, urothelial carcinoma.
BMS presses go on Nektar combo pivotal trials, despite data debate

The phase I/II PIVOT trial met the criteria needed to advance PD-1 inhibitor Opdivo (nivolumab) and CD122-biased agonist NKTR0214 into pivotal trials in melanoma, renal cell carcinoma and ... Nektar and BMS also reported initial stage 1 data in

More from news
Approximately 2 fully matching, plus 27 partially matching documents found.

Latest Intelligence

Europe vs the US: New drug product approvals

Tecentriq (for the treatment of urothelial carcinoma, only approved in the US), and Venclexta (for the treatment of chronic lymphocytic leukaemia, approved in the EU and US).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Strategic Planner, Healthcare Advertising Agency: Salary TBC

Experienced / Senior Medical Writer - Excellent Progression Oppo...: Excellent Salary and Benefits on offer

Editorial Assistants - Medical Communications agency - Cheshire: Excellent Remuneration Package

Senior Medical Writer: Salary TBC

Senior Medical Writer – Medical Communications – North West – In...: Excellent Remuneration Package

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Senior Account Manager / Account Director - MedComms - London: Highly competitive salary &package

Account Director, Medical Education: Salary TBC

Senior Copywriter: Salary TBC

Senior / Principal Medical Writers wanted - MedComms - Various U...: Excellent Remuneration Packages

Subscribe to our email news alerts

PMHub

Add my company

Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

eyeforpharma Marketing and Customer Innovation Europe: By Richard Springham...
The Golden Goose: Why it’s so hard for the US to curb runaway drug prices...
What is changing in cardiovascular disease care?: Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...